Anixa Biosciences Inc
Anixa Biosciences Inc (ANIX) Covered Calls
Anixa Biosciences Inc trades in the Biotechnology industry with an IV Rank of 95.63%, high versus the past year. ANIX's highest covered call setup is the $5.00 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 90.84% out of the money with 63 days to expiration, a 92.75% return until expiration, and a 537.35% theoretical annualized return. Across the setups shown, annualized returns run from 237.92% to 537.35% at strikes between $5.00 and $5.00, with 63 to 154 days to expiration, as of Nov 13, 2026.
Read more
Running ANIX covered calls helps you generate income from Anixa Biosciences Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ANIX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ANIX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ANIX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ANIX covered call is worth writing.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer.
| 2027-01-15 | 63 | 5.00 | 90.84 | 0.05 | 0.30 | 243.00 | 92.75 | 537.35 | -1.91 | +0.24 | 886 | 0.25 |
| 2027-04-16 | 154 | 5.00 | 90.84 | 0.25 | 0.80 | 263.00 | 100.38 | 237.92 | -9.54 | +0.44 | 548 | 0.55 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank95.63% High
- Market cap (M$)93
- 52 weeks high-51.10%
- 52 weeks low15.09%
- Analyst recommendationStrong Buy
1.00 - Target price$9.67
258.15% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2027-01-11
- P/E—
- Future P/E—
- EPS (ttm)-0.31
- EPS growth next 5 years0.99%
As of Nov 17, 2026